AUSTAR Partners with Leading Pharmaceutical Company to Drive Expansion of FDA-Standard Insulin Bulk Drug Workshop

Recently, AUSTAR has successfully completed the overall expansion and upgrading project of the bulk insulin production workshop for a leading Chinese insulin manufacturer. Building on the in-depth strategic cooperation established since 2015, AUSTAR delivers professional engineering services, empowering the client to consolidate its core global competitiveness with FDA-compliant high-standard production systems and advancing the global layout and commercial development of insulin products.

This project involves the expansion and upgrade of the client's first FDA-certified insulin bulk solution workshop. The entire construction process strictly complies with U.S. FDA regulations and ASME BPE biopharmaceutical industry standards. The project covers four core modules, including the construction of pharmaceutical-grade stainless steel process tanks and piping, supporting customized CIP cleaning systems, upgrading workshop automatic control systems, and expanding the storage and distribution systems for pharmaceutical water. Adhering to stringent standards in material selection, polishing precision and hygienic welding procedures, the project fully meets the high cleanliness, high sterility and high stability production requirements for insulin bulk solution. It complies with FDA on-site inspection criteria, laying a solid compliance foundation for the client's product registration and stable global supply.

This highly challenging expansion and renovation project was carried out within an operational and GMP-compliant production workshop, requiring seamless connection and data interoperability between new and existing equipment, pipelines, process parameters and automatic control systems. Leveraging extensive experience in constructing FDA-standard insulin workshops, AUSTAR effectively overcame key difficulties in construction and commissioning, eliminated interface discrepancies, and delivered a complete set of compliance validation documents, ensuring stable and consistent operation of the workshop production system.

Over the past decade, AUSTAR has fully supported the client in building standardized production lines and upgrading production capacity and intelligent systems. With comprehensive technical capabilities covering process systems, CIP systems, pharmaceutical water systems, as well as GMP and FDA compliance services, AUSTAR has helped the client break through international regulatory barriers. Moving forward, AUSTAR will continue to provide full-life-cycle engineering services to empower the upgrading of biopharmaceutical production lines and promote the high-quality global expansion of China's high-end pharmaceutical products.